Test question

[elbert5770]

@alzassistant Why does the ratio of amyloid beta 40:42 change in Alzheimer's disease?

[alzassistant]

Why the Aβ42/Aβ40 Ratio Changes in Alzheimer's Disease

Great question! The change in the Aβ42/Aβ40 ratio is one of the most important biomarkers in Alzheimer's disease. Let me break down what we know from the literature.

The Key Finding: Selective Aβ42 Depletion

The Aβ42/Aβ40 ratio decreases in Alzheimer's disease, primarily due to selective depletion of Aβ42 from cerebrospinal fluid (CSF) and plasma. According to research, this happens because:

"A low ratio reflects selective depletion of Aβ42 from the CSF due to deposition in the growing plaques." (PMC10087669)

Why Aβ42 Specifically?

Aβ42 is more aggregation-prone than Aβ40:

"The form ending at position 42 (Aβ42) is more prone to aggregation than shorter isoforms, of which Aβ40 is the most abundant." (PMC10013957)

This increased tendency to aggregate means that Aβ42 preferentially:

• Forms amyloid plaques in the brain
• Gets sequestered into growing plaques
• Becomes depleted from body fluids (CSF and plasma)

Meanwhile, Aβ40 levels remain relatively stable, causing the ratio to decrease.

The Molecular Mechanism: γ-Secretase Processing

Both Aβ40 and Aβ42 are produced by sequential cleavage of APP:

1. β-secretase (BACE1) makes the first cut, creating the N-terminus of Aβ
2. γ-secretase makes the final cut, determining the C-terminus

The critical point is that γ-secretase cleavage is imprecise:

"Cleavage by the γ-secretase complex is not precise; while the majority of Aβ peptides liberated by γ-secretase activity end at amino acid 40 (Aβ40), a small proportion end at amino acid 42 (Aβ42). It is this γ-secretase-dependent cleavage that is affected by most FAD mutations to cause excess generation of Aβ42 in FAD." (PMC2211305)

In Familial AD: Increased Aβ42 Production

In familial Alzheimer's disease (FAD), mutations in APP or presenilin genes increase Aβ42 production:

"Aβ is derived from APP and mutations in APP and PS increase Aβ42 production and cause FAD with nearly 100% penetrance... In FAD, the Aβ42 increase is present years before AD symptoms arise, suggesting that Aβ42 is likely to initiate AD pathophysiology." (PMC2211305)

This shifts the ratio by producing more Aβ42 relative to Aβ40.

Clinical Significance of the Ratio Change

The Aβ42/Aβ40 ratio is a robust biomarker:

In CSF:

• 40-60% reduction in AD patients
• High diagnostic accuracy (sensitivity ~96%, specificity ~91%)
• "Clear bimodal distribution" separating AD from controls

In Plasma:

• 8-15% reduction (smaller than CSF)
• Still detectable and useful for screening
• Changes occur in pre-symptomatic stages

"An important feature of plasma Aβ42/Aβ40 is that the levels are fully changed already during the pre-symptomatic disease stages." (PMC10087669)

Summary

The Aβ42/Aβ40 ratio changes in AD due to:

1. Selective aggregation: Aβ42 is more prone to forming plaques
2. Selective depletion: Aβ42 gets trapped in growing amyloid plaques
3. Relative stability: Aβ40 levels remain more constant
4. Result: Decreased ratio in body fluids

In familial cases, there's also increased production of Aβ42 due to mutations affecting γ-secretase processing, but the ultimate effect on the ratio in fluids is still driven by plaque deposition.

---

Key References:

• PMC10087669 - Blood biomarkers review
• PMC10013957 - CSF biomarker accuracy
• PMC2211305 - BACE1 and APP processing mechanisms

Would you like me to dive deeper into any specific aspect, such as the molecular details of γ-secretase cleavage or the use of this ratio in clinical diagnostics?